An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity
Journal article, 2014

Many efficacious cancer treatments cause significant cardiac morbidity, yet biomarkers or functional indices of early damage, which would allow monitoring and intervention, are lacking. In this study, we have utilized a rat model of progressive doxorubicin (DOX)-induced cardiomyopathy, applying multiple approaches, including cardiac magnetic resonance imaging (MRI), to provide the most comprehensive characterization to date of the timecourse of serological, pathological, and functional events underlying this toxicity. Hannover Wistar rats were dosed with 1.25 mg/kg DOX weekly for 8 weeks followed by a 4 week off-dosing "recovery" period. Electron microscopy of the myocardium revealed subcellular degeneration and marked mitochondrial changes after a single dose. Histopathological analysis revealed progressive cardiomyocyte degeneration, hypertrophy/cytomegaly, and extensive vacuolation after two doses. Extensive replacement fibrosis (quantified by Sirius red staining) developed during the off-dosing period. Functional indices assessed by cardiac MRI (including left ventricular ejection fraction (LVEF), cardiac output, and E/A ratio) declined progressively, reaching statistical significance after two doses and culminating in "clinical" LV dysfunction by 12 weeks. Significant increases in peak myocardial contrast enhancement and serological cardiac troponin I (cTnI) emerged after eight doses, importantly preceding the LVEF decline to < 50%. Troponin I levels positively correlated with delayed and peak gadolinium contrast enhancement, histopathological grading, and diastolic dysfunction. In summary, subcellular cardiomyocyte degeneration was the earliest marker, followed by progressive functional decline and histopathological manifestations. Myocardial contrast enhancement and elevations in cTnI occurred later. However, all indices predated "clinical" LV dysfunction and thus warrant further evaluation as predictive biomarkers. © The Author 2014.

Anthracycline

Cardiotoxicity

Cardiac MRI

Ejection fraction

Chemotherapy

Doxorubicin

Author

Laura Cove-Smith

University of Manchester

NHS Foundation Trust

Neil Woodhouse

AstraZeneca AB

Adam Hargreaves

AstraZeneca AB

J. Kirk

AstraZeneca AB

Susan Smith

AstraZeneca AB

Sally Price

AstraZeneca AB

Melanie Galvin

AstraZeneca AB

Catherine J Betts

AstraZeneca AB

Simon Brocklehurst

AstraZeneca AB

Alison Backen

University of Manchester

John Radford

University of Manchester

NHS Foundation Trust

Kim Linton

University of Manchester

NHS Foundation Trust

Toxicological Sciences

1096-6080 (ISSN) 1096-0929 (eISSN)

Vol. 140 1 3-15

Subject Categories (SSIF 2011)

Cardiac and Cardiovascular Systems

Neurology

Radiology, Nuclear Medicine and Medical Imaging

DOI

10.1093/toxsci/kfu057

PubMed

24675088

More information

Latest update

3/16/2025